Paid Stock Acquisition Rights Linked to Ordinary Profit
First written in FY2016. 2 of 28 entries say "Advanced", first in FY2017. Latest entry: FY2026.
26 other companies' latest entry also says "Other".
- FY2026Exercise Periods for the Sixth and Seventh Stock Acquisition Rights ExpiredAnnual report
「The exercise period for the Series 6 and Series 7 stock acquisition rights expired on 31 December 2025.」
The exercise period for the Series 6 and Series 7 stock acquisition rights issued after the business integration expired, and there was no unexercised balance of stock options as of the end of the period. - FY2026-H1Continued issuance through the exercise of share acquisition rightsAnnual report
「1 July 2025–31 December 2025 (Note) 10,710 91,822,812 5 4,821 5 447 (Note) Increase resulting from the exercise of stock acquisition rights.」
Exercise of stock acquisition rights continued from July to December 2025, increasing the total number of issued shares by 10,710 and both share capital and capital surplus by ¥5 million. - FY2025-H1Continued issuance through the exercise of share acquisition rightsAnnual report
「1 July 2024–31 December 2024 (Note) 16,317 91,795,092 8 4,804 8 431 (Note) Increase resulting from the exercise of stock acquisition rights.」
Exercise of stock acquisition rights continued from July to December 2024, increasing the total number of issued shares by 16,317 and both share capital and capital surplus by ¥8 million. - FY2024Progress in the exercise, lapse and expiration of stock acquisition rightsAnnual report
「Unexercised balance at beginning of period 691,866 Grant － Exercise 203,364 Lapse 215,901 Expiration 14,427 Unexercised balance at end of period 258,174」
During the fiscal year, stock acquisition rights equivalent to 203,364 shares were exercised, those equivalent to 215,901 shares lapsed, and those equivalent to 14,427 shares expired, leaving an unexercised balance equivalent to 258,174 shares at the end of the period. - FY2024-Q3Continued increase in shares and capital through the exercise of stock acquisition rightsAnnual report
「1 January 2024– 31 March 2024 (Note) 181,377 91,778,775 85 4,795 85 422 (Note) Increase resulting from the exercise of stock acquisition rights.」
Exercise of stock acquisition rights continued from January to March 2024, increasing the total number of issued shares by 181,377 and both share capital and capital surplus by ¥85 million. - FY2024-Q2Continued increase in shares and capital through the exercise of stock acquisition rightsAnnual report
「1 October 2023–31 December 2023 (Note) 18,900 91,597,398 12 4,710 12 336 (Note) Increase resulting from the exercise of stock acquisition rights.」
Exercise of stock acquisition rights continued from October to December 2023, increasing the total number of issued shares by 18,900 and both share capital and capital surplus by ¥12 million. - FY2024-Q1Expenses incurred upon satisfaction of stock acquisition rights exercise conditions and continued exerciseAnnual report
「One-time expense incurred upon satisfaction of stock acquisition rights exercise conditions」
A one-time expense was incurred upon satisfaction of the exercise conditions for the stock acquisition rights. In addition, from July to September 2023, 3,087 shares were issued through the exercise of stock acquisition rights, increasing both share capital and capital surplus by ¥2 million. - FY2023Progress in the exercise, lapse and expiration of stock acquisition rightsAnnual report
「Unexercised balance at beginning of period 1,339,754 Grant － Exercise 295,292 Lapse 232,596 Expiration 120,000 Unexercised balance at end of period 691,866」
During the fiscal year, stock acquisition rights equivalent to 295,292 shares were exercised, those equivalent to 232,596 shares lapsed, and those equivalent to 120,000 shares expired, leaving an unexercised balance equivalent to 691,866 shares at the end of the period. - FY2023-Q3Increase in shares and capital through the exercise of stock acquisition rightsAnnual report
「1 January 2023–31 March 2023 (Note) 185,535 91,561,929 94 4,687 94 313 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the third quarter of the fiscal year, exercise of stock acquisition rights continued, increasing the total number of issued shares by 185,535 and both share capital and capital surplus by ¥94 million. - FY2023-Q2Exercise of stock acquisition rights continuesAnnual report
「1 October 2022–31 December 2022 (Note) 91,865 91,376,394 28 4,592 28 219 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the second quarter of the fiscal year, exercise of stock acquisition rights continued, increasing the total number of issued shares by 91,865 and both share capital and capital surplus by ¥28 million. - FY2023-Q1Exercise of stock acquisition rights continuesAnnual report
「1 July 2022–30 September 2022 (Note) 4,410 91,284,529 2 4,563 2 190 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the quarter, exercise of stock acquisition rights continued, increasing the total number of issued shares by 4,410 and both share capital and capital surplus by ¥2 million. - FY2022Continued exercise and outstanding balance of stock acquisition rightsAnnual report
「Unexercised balance at beginning of period 1,767,733 Exercised 279,585 Unexercised balance at end of period 1,339,754」
During the fiscal year, stock acquisition rights equivalent to 279,585 shares were exercised, leaving an unexercised balance equivalent to 1,339,754 shares at the end of the period. The exercise period for the Series 1 paid stock acquisition rights runs through 24 December 2022. - FY2022-Q3Exercise of stock acquisition rights continuesAnnual report
「1 January 2022–31 March 2022 (Note) 204,718 91,214,796 101 4,541 101 167 (Note) Increase resulting from the exercise of stock acquisition rights.」
Exercise of stock acquisition rights continued from January to March 2022, increasing the total number of issued shares by 204,718 and both share capital and capital surplus by ¥101 million. - FY2022-Q2Exercise of stock acquisition rights continuedAnnual report
「1 October 2021–31 December 2021 (Note) 8,221 91,010,078 3 4,439 3 66 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the second quarter of the fiscal year, exercise of stock acquisition rights continued, increasing the total number of issued shares by 8,221 and both share capital and capital surplus by ¥3 million. - FY2022-Q1Exercise of stock acquisition rights continuesAnnual report
「1 July 2021–30 September 2021 (Note) 1,323 91,001,857 0 4,436 0 62 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the quarter, exercise of stock acquisition rights increased the total number of issued shares by 1,323. - FY2021Additional issuance of stock acquisition rights following the business integrationAnnual report
「Exercised 12,800 Unexercised balance 300,400 2021 Series 6 Stock Acquisition Rights Exercise period for stock acquisition rights 1 January 2022–31 December 2025 Common shares 670,635 2021 Series 7 Stock Acquisition Rights Exercise period for stock acquisition rights 1 January 2023–31 December 2025 Common shares 656,649」
The equivalent of 12,800 shares under the Series 1 paid stock acquisition rights was exercised, leaving the equivalent of 300,400 shares unexercised. In addition, Series 6 and Series 7 stock acquisition rights, subject to construction-related and engineering-related segment profit conditions, were newly granted in connection with the business integration. - FY2021-Q3Exercise of stock acquisition rights continuesAnnual report
「1 January 2021–31 March 2021 (Note) 1 6,400 42,934,100 1 4,418 1 45 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
Exercise of stock acquisition rights continued from January to March 2021, increasing the total number of issued shares by 6,400 and both share capital and capital surplus by ¥1 million. - FY2021-Q1Exercise of stock acquisition rights continuesAnnual report
「The increase resulted from the exercise of share acquisition rights.」
Exercise of stock acquisition rights continued from July to September 2020, increasing the total number of issued shares by 2,000. - FY2020Continued exercise of stock acquisition rights and disclosure of the remaining balanceAnnual report
「Exercised: 418,800 Remaining unexercised: 313,200」
During the current fiscal year, stock acquisition rights equivalent to 418,800 shares were exercised, and rights equivalent to 313,200 shares remain unexercised. - FY2020-Q2Continued issuance through the exercise of share acquisition rightsAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The exercise of stock acquisition rights continued from October through December 2019, increasing the total number of shares issued by 378,800. There was no new disclosure regarding achievement of the performance targets. - FY2019AchievedAnnual report
「Profit increased as revenue rose in each segment. Operating profit was ¥5,719 million, up 33.1% year on year; ordinary profit was ¥5,606 million, up 32.6%; and profit attributable to owners of the parent was ¥3,706 million, up 44.3%.」
Ordinary profit was ¥5,606 million, exceeding the final performance target of ¥5.0 billion for the 1st series of paid stock acquisition rights, applicable in any fiscal year from the fiscal year ending June 2016 through the fiscal year ending June 2020. - FY2019-Q3Exercise Price Adjustment Due to Stock SplitAnnual report
「In connection with this stock split, the exercise price per share for the stock acquisition rights issued by the Company will be adjusted as follows effective 1 July 2019. Board resolution date Name of stock acquisition rights Exercise price before adjustment Exercise price after adjustment 20 November 2015 1st series of paid stock acquisition rights ¥1,192 ¥596」
In connection with the stock split, the exercise price for the 1st series of paid stock acquisition rights will be adjusted from ¥1,192 to ¥596 effective 1 July 2019. No new achievement of the ordinary-profit-linked performance target was disclosed. - FY2019-Q2Exercise of stock acquisition rights continuedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The exercise of stock acquisition rights increased the total number of shares issued by 2,000 between October and December 2018. No new achievement of the ordinary-profit-linked performance target was disclosed. - FY2019-Q1Exercise of stock acquisition rights continuedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The exercise of stock acquisition rights increased the number of shares by 400 between July and September 2018. No new achievement of the ordinary-profit-linked performance target was disclosed. - FY2018-Q3Exercise of stock acquisition rights continuedAnnual report
「The Company has issued new shares upon the exercise of stock acquisition rights. As a result, during the first 3 quarters of the consolidated fiscal year, capital and capital reserves each increased by ¥1,542,332 thousand. At the end of the third quarter of the consolidated fiscal year, capital was ¥3,105,037 thousand and capital reserves were ¥2,095,037 thousand.」
The issuance of new shares through the exercise of stock acquisition rights continued, increasing capital and capital reserves by ¥1,542,332 thousand each during the first 3 quarters. - FY2018-Q1Exercise of stock acquisition rights occurredAnnual report
「During the period from 1 October 2017 to 31 October 2017, the exercise of stock acquisition rights increased the total number of shares issued by 800, and increased capital and capital reserves by ¥480 thousand each.」
The exercise of stock acquisition rights increased the number of shares by 800 and increased capital and capital reserves by ¥480 thousand each. There is no new disclosure regarding achievement of the ordinary-profit-linked performance target. - FY2017AdvancedAnnual report
「As a result, ordinary profit for the consolidated fiscal year was ¥3,185 million, up 26.0% year on year.」
Ordinary profit was ¥3.185 billion, exceeding the next performance target of ¥3.0 billion for the 1st series of paid stock acquisition rights, applicable in any fiscal year from the fiscal year ending June 2016 through the fiscal year ending June 2018. The final target of ¥5.0 billion has not been reached. - FY2016First statedAnnual report
「(a) Performance assessment fiscal year: fiscal year ended June 2016; performance target: ordinary profit of ¥2.3 billion; exercisable percentage: 20%. (b) Performance assessment period: the 3 fiscal years from the fiscal year ended June 2016 through the fiscal year ending June 2018; performance target: ordinary profit of ¥3.0 billion in any fiscal year; exercisable percentage: an additional 20% on top of (a). (c) Performance assessment period: the 3 fiscal years from the fiscal year ended June 2016 through the fiscal year ending June 2018; performance target: ordinary profit of ¥4.0 billion in any fiscal year; exercisable percentage: an additional 10% on top of (a) and (b). (d) Performance assessment period: the 5 fiscal years from the fiscal year ended June 2016 through the fiscal year ending June 2020; performance target: ordinary profit of ¥5.0 billion in any fiscal year; exercisable percentage: 100%.」
The stock acquisition rights included staged performance targets ranging from ¥2.3 billion to ¥5.0 billion in ordinary profit, with corresponding exercise percentages.